Wednesday, July 12, 2023

Maleimide-PEG-PLGA from PolySciTech used in development of immunotherapy for diabetes treatment

 

Autoimmune Type 1 diabetes is a chronic condition that affects 1.25 million in USA, in which the pancreas produces little to no insulin due to immune system self-attack. The use of nanoparticles can be applied to shifting the immunologic balance and reducing immune attack. Researchers at Harvard University, Università di Milano, University of Florida, Qatar University, University of Sharjah, and University of Maryland used PEG-PLGA (AK102) and Mal-PEG-PLGA (AI110) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create nanoparticles decorated with targeting ligand MECA-79 and loaded with anti-CD3 therapeutic. This research holds promise to improve diabetes treatment. Read more: Jung, Sungwook, Moufida Ben Nasr, Baharak Bahmani, Vera Usuelli, Jing Zhao, Gianmarco Sabiu, Andy Joe Seelam et al. "Nano‐Targeted Delivery of Immune Therapeutics in type 1 Diabetes." Advanced Materials (2023): 2300812. https://onlinelibrary.wiley.com/doi/abs/10.1002/adma.202300812

“Immune therapeutics hold great promise in the treatment of type 1 diabetes (T1D). Nonetheless, their progress has been hampered by limited efficacy, equipoise, or issues of safety. To address this, we developed a novel and specific nanodelivery platform for T1D that targets high endothelial venules (HEVs) presented in the pancreatic lymph nodes (PLNs) and pancreas. Our data indicate that the pancreata of non-obese diabetic (NOD) mice and patients with T1D are unique in their expression of newly formed HEVs. We encapsulated anti-CD3 mAb in PLGA-PEG nanoparticles (NPs), the surfaces of which were conjugated with MECA79 mAb that recognizes HEVs. Targeted delivery of these NPs improved accumulation of anti-CD3 mAb in both the PLNs and pancreata of NOD mice. Treatment of hyperglycemic NOD mice with MECA79-anti-CD3-NPs resulted in significant reversal of T1D compared to those that were untreated, treated with empty NPs, or provided free anti-CD3. This effect was associated with a significant reduction of T effector cell populations in the PLNs and a decreased production of pro-inflammatory cytokine in the mice treated with MECA79-anti-CD3-NPs. In sum, HEV-targeted therapeutics may be used as a means by which immune therapeutics can be delivered to PLNs and pancreata to suppress autoimmune diabetes effectively.”

No comments: